Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism
- PDF / 1,731,186 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 7 Downloads / 182 Views
ANNUAL ISSUE PAPER
Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism Eric Legius 1
&
Hilde Brems 1
Received: 25 May 2020 / Accepted: 23 June 2020 # Springer-Verlag GmbH Germany, part of Springer Nature 2020
Abstract Introduction Neurofibromatosis type 1 (NF1) is a frequent autosomal dominant disorder characterised by café-au-lait maculae (CALM), skinfold freckling, iris Lisch nodules and benign peripheral nerve sheath tumours (neurofibromas). Mechanism The NF1 gene is a tumour suppressor gene and NF1 individuals have an increased risk for a long list of tumours, all resulting from a second hit in the normal copy of the NF1 gene. Remarkably, some non-tumour phenotypes such as CALM and pseudarthrosis are also caused by a “second hit”. Germline mutations inactivating the NF1 gene show a large variability in genetic mechanisms ranging from single-nucleotide substitutions and somatic mosaicism to large deletions affecting neighbouring genes. Molecular confirmation of the clinical diagnosis is becoming increasingly more important to differentiate NF1 from other syndromes such as Legius syndrome, to investigate genotype-phenotype correlations relevant in 10% of cases and to detect somatic mosaicism. Surveillance and therapy Some degree of learning difficulties, attention deficit and social problems are observed in most children and affect quality of life. There is a large individual variability in complications and the evolution of the disease is difficult to predict. Specialised outpatient clinics for children have been widely established and are important for surveillance and guidance. Regular surveillance is also important for adolescents and adults because many tumour complications can be detected by wholebody MRI and treated even before symptoms develop and irreversible damage occurs. Recent data on nodular plexiform neurofibromas with continued growth in adolescents and young adults show that many of these tumours are premalignant lesions called atypical neurofibromatous neoplasm of uncertain biological potential (ANNUBP). Specific surveillance and timely local resection of these benign peripheral nerve sheath tumours might be important to prevent malignant degeneration. In the last years, targeted therapy with MEK inhibitors has shown promise to treat unresectable and symptomatic plexiform neurofibromas. Many more challenges remain to find the best way to monitor children and adults for potential complications and to find a satisfying cure for many complications in this disorder. Keywords Neurofibromatosis type 1 . café-au-lait maculae . Neurofibroma . Neurofibromin . MAPKinase
Introduction Neurofibromatosis type 1 (NF1) is the most frequent and wellknown autosomal dominant neurocutaneous syndrome with an estimated birth incidence of 1 in 2000 to 1 in 2500 [1–3]. In half of the cases, the syndrome is inherited from one of the parents and in the other half, the mutation originated de novo.
* Eric Legius [email protected] 1
Department of Human Genetics, University of
Data Loading...
